The optimistic outcomes of fetal-derived stem cell therapy for COVID-19 treatment might be due to having a higher proportion of active stem cells and a lower ratio of ACE/ACE2 in fetal-derived MSCs compared to other adult tissue-derived stem cells [111]. The gene discussed is ACE; the disease is COVID-19.